Earnings summaries and quarterly performance for SS Innovations International.
Research analysts covering SS Innovations International.
Recent press releases and 8-K filings for SSII.
SS Innovations Announces Preliminary Q4 and Full Year 2025 Revenue and Installations
SSII
Earnings
Guidance Update
New Projects/Investments
- SS Innovations International, Inc. announced preliminary unaudited revenue of approximately $15.0 million for the fourth quarter of 2025, an 85% increase from Q4 2024.
- For the full year 2025, the company expects preliminary unaudited revenue of approximately $43.0 million, marking a 108% increase over 2024.
- The company anticipates 37 SSi Mantra installations in Q4 2025 and 103 installations for the full year 2025, resulting in a cumulative installed base of 168 as of December 31, 2025.
- SS Innovations expects to complete the U.S. FDA review and obtain European Union CE marking certification for the SSi Mantra in the first half of 2026.
Jan 13, 2026, 1:35 PM
SS Innovations International Announces Preliminary Q4 and Full Year 2025 Results
SSII
Earnings
Guidance Update
Revenue Acceleration/Inflection
- SS Innovations International expects preliminary unaudited revenue of approximately $15.0 million for the fourth quarter of 2025, an 85% increase from Q4 2024, and approximately $43.0 million for the full year 2025, a 108% increase from 2024.
- The company anticipates 37 SSi Mantra installations in Q4 2025, up 68% year-over-year, and 103 installations for the full year 2025, marking a 119% increase from 2024.
- The cumulative SSi Mantra installed base reached 168 as of December 31, 2025, representing a 158% increase from the prior year.
- SS Innovations International expects the U.S. FDA to complete its review of the 510(k) premarket notification for the SSi Mantra in the first half of 2026, with anticipation of obtaining European Union CE marking certification also in the first half of 2026.
Jan 13, 2026, 1:30 PM
SS Innovations International Appoints Milan Rao as Global COO and CFO
SSII
CFO Change
Management Change
Executive Compensation
- SS Innovations International, Inc. (SSII) appointed Milan Rao as Global Chief Operating Officer (a newly created position) and Chief Financial Officer, effective January 16, 2026.
- Mr. Rao succeeds Naveen Kumar Amar, who resigned as CFO on January 2, 2026, for personal reasons.
- Mr. Rao brings over three decades of executive leadership experience to the company, including roles at GE Healthcare and Wipro Limited.
- His compensation includes a monthly base compensation of $41,667 and a stock grant of 120,000 shares of common stock, vesting in equal monthly installments over a one-year term.
Jan 8, 2026, 10:05 PM
SS Innovations International Appoints Milan Rao as Global COO and CFO
SSII
Management Change
CFO Change
Hiring
- SS Innovations International (SSII) has appointed Milan Rao as its Global Chief Operating Officer and Chief Financial Officer.
- The Global Chief Operating Officer role is a newly created position.
- Mr. Rao will succeed Naveen Kumar Amar as Chief Financial Officer, following Mr. Amar's resignation for personal reasons.
- Mr. Rao brings over three decades of executive leadership experience in technology-enabled transformation, operational efficiency, and growth, including roles at GE Healthcare, Wipro Limited, Morgan Stanley, and Citibank.
Jan 8, 2026, 10:00 PM
SS Innovations International, Inc. Develops New 5-millimeter Surgical Instruments
SSII
Product Launch
New Projects/Investments
- On January 6, 2026, SS Innovations International, Inc. announced the completion of five new 5-millimeter surgical instruments for its SSi Mantra surgical robotic system.
- These instruments are designed to advance robotic surgery in pediatric, cardiac, and head and neck specialties, aiming to serve large, underserved patient segments.
- As of December 31, 2025, the company reported an installed base of 168 SSi Mantra systems across 153 hospitals, with over 7,800 surgical procedures performed.
Jan 6, 2026, 1:42 PM
SS Innovations International Submits SSi Mantra for FDA 510(k) Premarket Notification
SSII
Product Launch
New Projects/Investments
- SS Innovations International, Inc. submitted a 510(k) premarket notification to the FDA for its SSi Mantra surgical robotic system on December 5, 2025.
- The submission covers multiple specialty procedure types, including general, urological, colorectal, gynecological, and cardiac surgeries.
- The company chose the 510(k) pathway to potentially benefit from speed and cost efficiencies, with the FDA's goal to complete reviews within 90 days.
- As of November 30, 2025, the SSi Mantra had a cumulative installed base of 138 systems across eight countries, with 137 hospitals having installed the system and over 7,300 surgical procedures performed.
- SS Innovations is also pursuing European Union CE marking certification for the SSi Mantra, which it expects to obtain in the first half of 2026.
Dec 8, 2025, 1:35 PM
SS Innovations International, Inc. Reports Strong Revenue Growth and Global Expansion
SSII
Revenue Acceleration/Inflection
New Projects/Investments
- SS Innovations International, Inc. reported revenue of $27.95 million for the nine months ended September 30, 2025, marking a 123% increase from $12.53 million in the same period of 2024. The gross margin for 9M 2025 improved to 47.1% from 35.8% in 9M 2024.
- As of September 30, 2025, the company had 127 SSi Mantra Systems installed and 6,057 total surgeries performed, with the system marketed or approved in 8 countries.
- The company is actively pursuing global expansion, with US FDA Market Clearance and EU CE Marking both anticipated in H1 2026. SS Innovations also pioneered telesurgery, performing the first intercontinental robotic cardiac telesurgery in July 2025.
- For the nine months ended September 30, 2025, diluted EPS was $(0.05), and the company held $11.71 million in cash as of September 30, 2025.
Nov 6, 2025, 9:07 PM
SS Innovations Announces Successful Completion of First Telesurgery with New Console
SSII
Product Launch
New Projects/Investments
- SS Innovations International, Inc. announced on November 6, 2025, the successful completion of the first telesurgery performed with its new SSi Mantra Tele Surgeon Console (TSC).
- The telesurgery, a robotic assisted coronary artery bypass, was conducted on October 17, 2025, by CEO Dr. Sudhir Srivastava from his residence in New Delhi, India, on a patient 185 miles away in Jaipur, India.
- The TSC is a compact, portable, chair-based console designed to expand access to surgical expertise by enabling telesurgeries from a wide range of settings, including physician offices.
Nov 6, 2025, 1:30 PM
SS Innovations International Reports Strong Q3 2025 Financial Results and CFO Appointment
SSII
Earnings
Revenue Acceleration/Inflection
CFO Change
- Revenue for the third quarter of 2025 increased 192.5% year-over-year to $12.8 million, driven by higher SSi Mantra 3 unit sales.
- The company reported a net loss of $3.7 million, or $(0.02) per diluted share, for the third quarter of 2025.
- SSi Mantra surgical robotic system installations significantly increased by 350.0% to 27 in Q3 2025 compared to Q3 2024, bringing the cumulative installed base to 127 systems.
- SS Innovations completed a human factors validation study in September 2025, which is a key component for its planned 510(k) premarket notification to the FDA in the fourth quarter of 2025.
- Naveen Kumar Amar was appointed as Chief Financial Officer on September 26, 2025.
Oct 28, 2025, 8:45 PM
SS Innovations International, Inc. Reports Strong Growth and Global Expansion in October 2025 Presentation
SSII
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
- SS Innovations International, Inc. (SSII) reported significant revenue growth, increasing from $5.6 million in 2023 to $20.6 million in 2024, a 251% increase, and from $8.1 million in 1H 2024 to $15.1 million in 1H 2025, an 86% increase.
- The company's SSi Mantra Systems Installed grew 191% from 43 as of September 30, 2024, to 125 as of September 30, 2025, with completed procedures increasing 182% to 6,053 over the same period.
- Gross margin improved from 12.3% in 2023 to 40.9% in 2024, and from 26.6% in 1H 2024 to 46.3% in 1H 2025, with recurring revenue exceeding 10% of total revenue as of Q2 2025.
- SSII is expanding globally, with its SSi Mantra system marketed/approved in 8 countries and anticipated US FDA and EU CE market clearances in H1 2026.
- The company differentiates its surgical robotic technology, including pioneering telesurgery capabilities, by offering it at approximately one-third the cost of competing systems.
Oct 14, 2025, 10:07 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more